OS Therapies (OSTX) FDA Meeting Request Granted

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/19/2026

1. SPY
2. CRWV
3. EYPT
4. NVDA
5. CLF
6. TSLA
7. SLN
8. SLGN
9. ETD
10. IRON

Go back to OS Therapies (OSTX) FDA Meeting Request Granted

OS Therapies FDA Meeting Request Granted

April 22, 2025 7:40 AM EDT

Written response-only meeting to align analysis plan of surrogate endpoint to support Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma Analysis to be featured at keynote presentation closing out major osteosarcoma conference MIB Factor on June 28, 2025 at 3:30pm MDT

NEW YORK--(BUSINESS WIRE)-- OS Therapies (NYSE-A: OSTX) (OS Therapies or the Company), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that the US Food & Drug Administration (FDA) granted the Companys meeting request to gain... More